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Hepatitis C virus (HCV) infection has become a global public health burden costing billions
of dollars in health care annually. Even with rapidly advancing scientiﬁc technologies this
disease still poses a signiﬁcant threat due to a lack of vaccines and affordable treatment
options. The immune correlates of protection and predisposing factors toward chronicity
remain major obstacles to development of HCV vaccines and immunotherapeutics due,
at least in part, to lack of a tangible infection animal model. This review discusses the
currently available animal models for HCV disease with a primary focus on GB virus B (GBV-
B) infection of New World primates that recapitulates the dual Hepacivirus phenotypes
of acute viral clearance and chronic pathologic disease. HCV and GBV-B are also closely
phylogenetically related and advances in characterization of the immune systems of
NewWorld primates have already led to the use of this model for drug testing and vaccine
trials. Herein, we discuss the beneﬁts and caveats of theGBV-B infectionmodel and discuss
potential avenues for future development of novel vaccines and immunotherapies.
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Hepatitis C virus (HCV) is a major chronic disease that has
infected greater than 150 million people worldwide. Given the
breadth and duration of infection HCV disease could result in
an economic crisis reaching into the 100s of billions within the
next decade. Although acute infection is usually asymptomatic
with self-resolution, 55–85% of infected persons develop chronic
disease that can lead to progressive hepatic ﬁbrosis, cirrhosis,
and hepatocellular carcinoma (HCC; Hoofnagle, 2002) which is
often fatal without treatment. There is also a strong association
of HCV infection with extra-hepatic diseases such as cryoglob-
ulinemia vasculitis (Luppi et al., 1998), diabetes (Mehta et al.,
2000), thyroid disease (Pateron et al., 1992), lichen planus (Jubert
et al., 1994), and neuropsychiatric conditions such as depression
(Thomas, 2013). This is complicated by the fact that approxi-
mately only half of individuals are aware of their HCV status
(Denniston et al., 2012), due, at least in part, to the rarity of symp-
toms in acute HCV infection. In 2007, mortality due to HCV
infection surpassed that of HIV in the United States (Ly et al.,
2012).
HCV DISEASE IN HUMANS
Hepatitis C virus was ﬁrst identiﬁed by Choo et al. (1989) as the
etiologic agent of non-A, non-B hepatitis. HCV is an enveloped,
single-stranded, positive sense RNA virus belonging to the Hep-
acivirus genus within the Flaviviridae family. The genome is 9.6 kb
with a single open reading frame (ORF) that encodes a polyprotein
which is further cleaved to yield 10 mature viral proteins namely
the structural proteins (C,E1, E2) andnon-structural proteins (p7,
NS2, NS3, NS4A, NS4B, NS5A, NS5B; Hellen and Pestova, 1999;
Lohmann, 2013). The envelope proteins (E1 and E2) and NS1 are
encoded from themost variable regions of the HCV genomewhile
NS5B codes for the RNA-dependent RNApolymerase (RdRp) that
is more highly conserved. HCV strains are classiﬁed into seven
genotypes and 67 subtypes (Smith et al., 2014) based on sequence
heterogeneity. Genotypes 1 and 2 are distributed globally while
genotype 3 predominates in Southeast Asia, genotype 4 in most
of Africa, genotype 5 in South Africa, and genotype 6 primarily
in Hong Kong and Vietnam (Gower et al., 2014). A genotype 7
variant has been conﬁrmed in only one Canadian patient who
had emigrated from the Democratic republic of Congo (Murphy
et al., 2007; Smith et al., 2014). In the US, 70% of HCV infections
are due to genotype 1 (Gower et al., 2014). Transmission of HCV
occurs primarily through exposure to HCV-infected blood with
an average incubation period of 6–10 weeks (Alter et al., 1989;
Barrera et al., 1995). Increased alanine aminotransferase (ALT)
levels, as a marker for liver damage, are also observed within
8–12 weeks after exposure (Rehermann, 2009). Many individuals
clear the virus within 6–12 months, but the outcome of the infec-
tion depends on multiple factors including host genetics, virus
strain, and virus-speciﬁc immunity (Abdel-Hakeem and Shoukry,
2014). Ethnicity, sex, alcohol abuse, and co-infections can also
contribute to the outcome of infection (Thomas et al., 2000; Schiff
and Ozden, 2003; Baden et al., 2014). However, the full spec-
trum of factors that dictate clearance versus chronicity remains
unknown.
Traditionally, therapy for chronic HCV has utilized a com-
bination of pegylated-IFN-α and ribavirin (Manns et al., 2001;
Fried et al., 2002), and later direct-acting antivirals Boceprevir
and Telaprevir in combination with pegylated IFN-α and ribavirin
(Jacobson et al., 2011; Poordad et al., 2011). Recently, Sofosbuvir,
a nucleotide analog HCV NS5B polymerase inhibitor developed
by Gilead, has been approved as part of an antiviral regimen
(Keating and Vaidya, 2014). This represents a breakthrough in
HCV therapeutics since Sofosbuvir is a simpliﬁed once-daily oral
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treatment (Cholongitas and Papatheodoridis, 2014; Keating and
Vaidya, 2014). However, the high cost and sophisticated clinical
monitoring required will likely make implementation challenging
in developing countries.
Despite two decades of research, no vaccine for HCV is avail-
able. Several candidate vaccines that reached the stage of Phase
I or II clinical trials did not progress further (Xue et al., 2014;
Zingaretti et al., 2014). One of the major challenges (summa-
rized in Table 1) for vaccine development is the lack of small
animal models that would allow the study of HCV infection,
genetic variability of host defenses, and immune modulatory
mechanisms induced by the virus. GBV-B is phylogenetically
a close relative of HCV and infects only New World monkeys
such as tamarins and marmosets (Muerhoff et al., 1995; Ohba
et al., 1996). Although GBV-B causes acute hepatitis with few
cases of persistence, it has been used as a surrogate model for
HCV infection in various studies to understand pathogenesis
and to demonstrate candidate antiviral activity (Beames et al.,
2000, 2001; Bright et al., 2004; Iwasaki et al., 2011). Even the dif-
ferential infection proﬁles between the two viruses could prove
helpful in grasping the immune evasion strategies of HCV. For
example, the HCV non-structural protein 5A (NS5A), impli-
cated in establishing persistence, modulates the Ras-Erk signaling
pathway (Mankouri et al., 2008a), whereas the GBV-B NS5A
protein does not block this pathway and also differs in its cel-
lular distribution (Mankouri et al., 2008b). This suggests that
the altered mechanism of NS5A in HCV infection could be
responsible for the chronicity of HCV in humans. Thus, both
the similarities and the contrasts of the GBV-B model with the
HCV infection can serve to broaden the knowledge of HCV
pathogenesis.
HISTORY OF GBV-B
In an attempt to isolate and identify the etiologic agent(s)
responsible for non-A, non-B hepatitis, Deinhardt et al. (1967)
inoculated tamarins and marmosets with the sera from patients
with severe hepatitis. The serum from one individual, a sur-
geon whose initials were GB, was found to cause hepatitis in
four challenged tamarins. Serial passages of the infected tamarin
sera also caused hepatitis in some animals. The 11th passage
of this serum (H205 GB pass 11 serum) was demonstrated
to be infectious in most tamarins and later was used as the
primary virus source for subsequent studies (Deinhardt et al.,
1975; Muerhoff et al., 1995; Simons et al., 1995b; Bukh et al.,
1999, 2001). Interestingly, the H205 GB pass 11 serum was
found to be non-infectious in chimpanzees (Tabor et al., 1980).
Reciprocally, tamarins were not infected by HCV (Garson et al.,
1997) implying that theGB infectious agent andHCV are different
entities.
In Simons et al. (1995b) two viruses were identiﬁed from the
serum of a tamarin infected with the H205 GB pass 11 serum
and were termed GBV-A and GVB-B. The genomic structure
of both the GB agents were similar to the Flaviviridae family
of viruses. GBV-B in particular was found to be closely related
to HCV based on amino acid sequence alignments and phylo-
genetic analyses (Table 2; Muerhoff et al., 1995). A third virus,
GBV-C, was also identiﬁed in human serum samples by the
usage of degenerate oligonucleotides that amplify related viral
sequences (Simons et al., 1995a). GBV-C was later determined
to be the same virus as hepatitis G virus (HGV; Linnen et al.,
1996). GBV-A was identiﬁed as a common primate virus with
viral genomes identiﬁed in Sanguinus,Callithrix, andAotus species
(Bukh and Apgar, 1997). GBV-A does not appear to cause hep-
atitis, but can persistently infect New World monkeys with no
obvious disease symptoms (Bukh and Apgar, 1997). Phyloge-
netic analysis showed that HCV and GBV-B were closely related
while GBV-A and GBV-C form a separate cluster (Muerhoff et al.,
1995; Simons et al., 1995a). The GBV-A and GBV-C viruses
have now been classiﬁed under a different genus, Pegivirus, and
renamed as simianpegivirus (SPgV) andhumanpegivirus (HPgV)
respectively (Stapleton et al., 2011). Unlike GBV-A, GBV-B is
not commonly found in New World monkeys and its natu-
ral host range is still unknown. Experimental inoculation with
GBV-B results in elevated liver enzymes in tamarins and can
afford protection against GBV-B re-infection (Schaluder et al.,
1995). Further, development of acute hepatitis in tamarins by
transfection studies with RNA transcripts of an infectious clone
of GBV-B conﬁrmed the hepatotropism of GBV-B (Bukh et al.,
1999).
OTHER HEPACIVIRUSES
The origin of HCV in humans is still not completely understood as
no HCV or HCV-like viruses have been discovered in Old World
monkeys. To understand the evolutionary origin of HCV and to
identify and characterize animal viral homologs (Table 2), the sera
of multiple non-primate species were screened for the presence of
hepaciviruses (Burbelo et al., 2012). Canine hepacivirus (CHV),
which has just 50% nucleotide sequence divergence from HCV,
was found to cause a respiratory disease in dogs associated with
high virus replication in the respiratory tract (Kapoor et al., 2011).
Serological analysis revealed the presence of virus variants similar
to CHV in horses, termed as non-primate hepaciviruses (NPHVs),
with rates of persistence greater than 20% and that cluster with
the canine/equine clade (Burbelo et al., 2012). Acute and chronic
Table 1 | Challenges in study and control of HCV.
Genetic diversity of the virus Genotypes are at least 30% divergent in nucleotide sequence
Quasispecies variation introduced by error prone RNA dependent RNA polymerase (RdRp)
Propagation of virus in vitro Difﬁculty in isolation and propagation of HCV in cell lines
Vaccine development Limited human studies in HCV at-risk populations
Lack of suitable animal models to understand viral pathogenesis and execute vaccine studies
Treatment Expensive, limited availability
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Table 2 | Hepatitis C virus and related flaviviruses.
Nucleotide sequence homology to
HCV based on NS3 and NS5b genes
Disease characteristics
Hepacivirus
GBV-B 48–62% (Muerhoff et al., 1995) Infects NewWorld monkeys; hepatotrophic; acute hepatitis; spontaneous
clearance in most cases (Stapleton et al., 2011)
CHV 50% (Kapoor et al., 2011; Pfaender
et al., 2014)
Infects dogs; not associated with liver disease; virus found in nasal samples
NHPV (CHV-like virus) Infects horses; associated with acute and chronic infection of liver (Pfaender
et al., 2014)
Pegivirus
GBV-A 53–55% (Muerhoff et al., 1995) Infects NewWorld monkeys; lymphotrophic; life-long infection; no apparent
disease (Stapleton et al., 2011)
GBV-C 40–50% (Linnen et al., 1996) Infects humans; lymphotrophic; persistent infection; no evidence of liver damage
(Stapleton et al., 2011)
GBV-D 41% (Epstein et al., 2010) Infects bats; no apparent hepatic dysfunction (Epstein et al., 2010)
hepatitis has been associated with NHPV infection in horses with
greater than 60% clearance of infection within ﬁrst 2 months
of infection (Pfaender et al., 2014). Novel hepaciviruses have also
been isolated from European bank voles and South African four-
striped grass mice and although these viruses are related to GBV-B
their ability to cause disease remains to be determined (Drexler
et al., 2013).
MODELS OF HCV INFECTION
CHIMPANZEE
Chimpanzees (Pan troglodytes) were the ﬁrst animal model for
HCV infection and have contributed signiﬁcantly to understand-
ing the natural history of HCV (Houghton, 2009; Table 3).
Chimpanzees also played a critical role in discovery of HCV
(Alter et al., 1978), and in the absence of efﬁcient cell cul-
ture systems, most infectious clones of HCV were developed in
vivo (Kolykhalov et al., 1997; Yanagi et al., 1997). Chimpanzees
have also been the primary model for evaluation of various
antivirals and vaccine modalities (Choo et al., 1994; Folgori
et al., 2006; Carroll et al., 2009; Summa et al., 2012; Callendret
et al., 2014). Similar to HCV infection in humans, infection of
chimpanzees can result in either an acutely cleared disease or
chronic infection (Walker, 1997; Major et al., 2004). Acute infec-
tion is characterized by early appearance of viremia (within a
week) reaching peak viral titers of 105–107 genome copies/ml
in plasma (Walker, 1997; Bukh, 2004). Antibodies against HCV
protein are generally detected within the ﬁrst 2 months of infec-
tion (Bukh, 2004). Hepatitis is evidenced by elevated serum
liver enzyme values and necroinﬂammatory changes in the liver.
Approximately 60% of infected chimpanzees develop chronic dis-
ease (Abe et al., 1992), characterized by persistent viremia and
mild hepatitis. Unfortunately, the use of chimpanzees as an
animal model for HCV continues to be limited due to their
low availability, high expense, ethical concerns, and a disease
course signiﬁcantly attenuated compared to humans (Bukh,
2004).
TREE SHREW
The northern tree shrew (Tupaia belangeri) is a non-rodent small
mammal indigenous to Southeast Asia, and other than chim-
panzees and humans, tree shrews are the only other species
known to be susceptible to HCV infection (Xie et al., 1998). In
a 3-year longitudinal study (Amako et al., 2010) persistent liver
infection was found in some animals and included some his-
tological indications of liver disease such as steatosis, ﬁbrosis,
and cirrhosis. Viremia and serum antibody levels were intermit-
tent, and in general the course of infection was transient and
self-resolving. Although infected tree shrews have been used for
metabolomic analyses to identify biomarkers associatedwithHCV
infection (Sun et al., 2013), the limited virus replication and lack
of species-speciﬁc reagents make tree shrews unlikely to become a
viable model (Table 3).
MOUSE MODELS
Although mice are naturally resistant to HCV infection, human-
ized chimeric mice with normal human hepatocytes exhibit
prolonged infection following inoculation with HCV (Mercer
et al., 2001). This model has been very helpful for preliminary
antiviral drug evaluation, but offers little for the study of HCV
pathogenesis since the chimeric mice are immunodeﬁcient. Ploss
et al. (2009) generated transgenic mice expressing human CD81,
scavenger receptor typeB class1, claudin 1, andOCLNand infected
them with HCV. This humanized model allowed for the investiga-
tion of HCV co-receptor biology in vivo using antibodies against
CD81 and E2 to inhibit viral entry, but was limited by inefﬁ-
cient replication and induction of immune responses against the
adenovirus vector, which was used to express the human receptors
(Table 3).
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Table 3 | Animal models for HCV.
Model Advantages Limitations
Chimpanzee HCV discovery; in vivo virus replication Expensive; limited availability; lack of liver ﬁbrosis; low
chronicity rate; ethical concerns
Tree shrew Small animal model susceptible to HCV infection Lack of chronicity; only transient viremia
Humanized mice model Useful for immunization and challenge studies Low level of viral replication; lack of progressive liver
pathology
GBV-B infection of NewWorld monkeys GBV-B closely related to HCV; analogous disease
course to HCV
Low frequency of chronic disease
Chimeric GBV-B infection of NewWorld
monkeys
Antiviral testing Inability to cause chronic infection
CHARACTERISTICS/NATURAL HISTORY OF GBV-B INFECTION
VIROLOGY
Similar to HCV, GBV-B has a positive-sense single stranded RNA
genome and a single ORF encoding the structural (core, E1 and
E2 proteins) and the non-structural (p13, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) proteins (Muerhoff et al., 1995). The
non-structural proteins are essential for replication, as is the 5′
UTR that directs translation and release of the viral RdRp ini-
tiating replication (De Tomassi et al., 2002; Warter et al., 2009).
Similar to the p7 protein of HCV, GBV-B also has a 13-KDa
protein, p13, located between E2 and NS2 that is essential for
viability (Takikawa et al., 2006). Only short regions of nucleotide
sequence similarity are shared by GBV-B and HCV includ-
ing a 130-nucleotide segment of 62% homology in the NS3
region and a 516-nucleotide segment of NS5 of 68% homol-
ogy (Muerhoff et al., 1995). The polyproteins of HCV and
GBV-B have approximately 25–30% homology at the amino
acid level, but the 5′ and 3′ UTR are more distinct (Muer-
hoff et al., 1995; Rijnbrand et al., 2000). The NS2 protein of
GBV-B shares membrane topology and has cysteine protease
activity similar to HCV (Boukadida et al., 2014). At a func-
tional level, the NS3 protease of GBV-B can correctly process
the HCV polyprotein (Scarselli et al., 1997) and HCV/GBVB
chimeric NS3 proteins are enzymatically active (Butkiewicz et al.,
2000). Interestingly, while both HCV and GBV-B NS5A pro-
teins activate the p13 kinase pathway, HCV NS5A blocks the
Ras-Erk pathway, whereas GBV-B NS5A does not (Macdonald
et al., 2003, 2004; Mankouri et al., 2008b). Despite an error-prone
RdRp, very few amino acid substitutions have been observed,
limiting the quasispecies variation of GBV-B in infected ani-
mals (McGarvey et al., 2008). Unlike HCV, no hypervariable
region was found in the E2 gene of GBV-B in a study by
Nam et al. (2004) and McGarvey et al. (2008) calculated the
mutation rate of GBV-B to be 0.6 × 10−3 nucleotide substi-
tutions/site/year. By comparison, the error rate for HCV RdRp
has been estimated at 1.4 to 1.9 × 10−3 nucleotide substitu-
tions/genome/site/year (Ogata et al., 1991; Okamoto et al., 1992).
These virological differences likely account for the signiﬁcant
differences in quasispecies diversity when comparing GBV-B
and HCV.
PATHOGENESIS
GB virus B is hepatotropic, but has been shown to disseminate
to hematolymphoid and genital tissues, including lymph nodes,
spleen, PBMC, kidney, testis, and bone marrow (Ishii et al., 2007),
much like HCV. The course of experimental GBV-B infection in
NewWorld monkeys usually results in acute hepatitis that resolves
within 2–3 months post-infection with signiﬁcant increases in
serum enzymes such as ALT and isocitrate dehydrogenase (Lan-
ford et al., 2003; Bright et al., 2004; Weatherford et al., 2009a).
GBV-B infection leads to a rapid rise in viremia reaching peak lev-
els of 107–1010 genomic equivalents (GEs)/ml by weeks 2–3 and
then plateaus before clearance (Jacob et al., 2004; Woollard et al.,
2008). Different from HCV, the liver enzyme glutamate dehydro-
genase has been shown to be associated with viral clearance and
hepatocyte destruction, rather than serumALT levels (Bright et al.,
2004). In liver, degeneration and apoptosis of hepatocytes and
disruption and dilation of sinusoids have been observed patho-
logically in GBV-B infected animals (Martin et al., 2003; Jacob
et al., 2004). In a marmoset study by Weatherford et al. (2009a),
two disease phenotypes were observed – susceptible and partially
resistant. Upon further passaging, the GBV-B virus was able to
adapt even in partially resistant animals. GBV-B also infects owl
monkeys of the Cebidae family but pathogenesis is signiﬁcantly
attenuated as indicated by peak viral titer 2–3 logs lower and
milder hepatitis as compared to tamarins and marmosets (Bukh
et al., 2001).
VIRUS PERSISTENCE
A major difference between HCV and GBV-B infections is the
chronic nature of HCV (Table 3). Generally GBV-B causes an
acute infection, although a few cases of chronicity have been
reported. Viral persistence for 2 years has been reported in a
tamarin infected by intrahepatic inoculation with a synthetic
viral RNA before spontaneous resolution (Martin et al., 2003).
In another study transfection with a poly (U) tract deletion
mutant rendered a tamarin persistently infected until its death
at week 90, whereas in other tamarins, acute resolving infection
with clearance at week 12 was observed (Nam et al., 2004). In
infected marmosets (Jacob et al., 2004), early peak viremia was
followed by clearance within 8 weeks in some animals whereas
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other animals with delayed peak viral load remained viremic up
to 6 months. Similarly, Iwasaki et al. (2011) showed that two out
of four marmosets infected with a molecular clone, pGBB, devel-
oped long-term chronic infection for up to 3 years with recurrent
viremia at low levels, similar to chronic infections in chimpanzees.
In efforts to increase persistence in the GBV-B model, immuno-
suppressive drugs have been utilized. Treatment with FK506 in
marmosets prior to GBV-B inoculation resulted in higher viral
loads and severe liver pathology but didnot lead to viral persistence
(Jacob et al., 2004). Inmost infection studies that showed viral per-
sistence, virus from persistently infected animals did not result in
chronic infections when transferred to other recipients. This sug-
gests that persistence may be primarily dependent on individual
host factors.
IMMUNOLOGY
One of the ﬁrst responses toHCV infection in the liver is induction
of type I interferons that are thought to aid in viral clearance. How-
ever,HCV inactivates early innate antiviral defenses via its NS3/4A
protease, which has been postulated to lead to persistence (Foy
et al., 2003, 2005; Li et al., 2005; Meylan et al., 2005). Similarly, the
GBV-B NS3/4A protease inhibits IFN-inducing pathways, notably
RIG-I signaling (Chen et al., 2007).When primary hepatocyte cul-
tures were exposed to IFN-α prior to GBV-B infection, potent
antiviral activity blocked virus infection (Chavez et al., 2009). By
comparison, in cultures with pre-established GBV-B infection
there was reduced antiviral activity, suggesting replicating virus
could exert anti-IFN actions.
Much like HCV, T cell immunity has been correlated with
viral clearance in marmosets infected with GBV-B (Woollard
et al., 2008). Virus-speciﬁc T cells were detected in blood at
7 weeks post-infection, coinciding with viral clearance and GBV-
B speciﬁc IFN-γ responses at week 5 post-infection coincided
with a 100-fold reduction in viral load. Virus-speciﬁc T cells
have also been found to accumulate in the liver of infected
marmosets, and the majority of the T cell responses (based
on IFN-γ ELIspot) are generated against epitopes in the NS3
and NS4A proteins (Woollard et al., 2008). Upon re-infection
of marmosets, the sharp increase in the T cell response sug-
gests the mobilization of memory T cell responses even though
no take of infection was observed (Woollard et al., 2008). In
marmosets infected with a molecular clone of GBV-B, persis-
tent viremia for 6 months was accompanied by marked inﬂux
of MHC class I restricted CD8+ T lymphocytes associated with
hepatic pathology (Jacob et al., 2004). This is in agreement with
studies that have shown predominance of CD8+ T cells in the
liver during chronic HCV contributing to liver injury (Fiore et al.,
1997).
Unlike T cell immunity, the humoral response to GBV-B infec-
tion is less well-characterized. Anti-NS3 antibody production
peaks toward the end of infection and declines following clear-
ance (Beames et al., 2000). The antibody levels fall rapidly in the
absence of viral replication (Beames et al., 2000), which is similar
to chimpanzees infected with HCV (Bassett et al., 1998). However,
in multiple instances a delayed antibody response has been asso-
ciated with GBV-B persistence (Martin et al., 2003; Iwasaki et al.,
2011).
GBV-B CHIMERAS
Attempts to improve on the GBV-B model have resulted in
construction of chimeric viruses where functional segments of
the HCV genome have been incorporated while retaining the
ability of GBV-B to replicate and cause liver disease in small
primates. These chimeras are extremely valuable for testing can-
didate therapeutics by targeting speciﬁc HCV sequences, but their
utility has been marred by difﬁculties in maintaining efﬁcient
take of virus and persistent replication. In HCV infection the
IRES directly binds to 40S ribosomal subunit and is a prime
candidate target for drug therapeutics. Rijnbrand et al. (2005)
constructed a chimeric RNA encoding domain III from the HCV
IRES element and while the virus was found to be replication
competent, replication levels were generally low and generated
adaptive mutations that were necessary for efﬁcient replication.
The same chimeric infection inmarmosets displayedwide-ranging
phenotypes from susceptible to resistant as seen in wild-type
GBV-B infection (Weatherford et al., 2009b). Unlike wild-type
virus, the chimeric virus failed to adapt in the resistant mar-
mosets on serial passages, indicating loss of ﬁtness (Weatherford
et al., 2009b). The ﬁrst 27 to 31 N-terminal amino acids of the
HCV E2 protein hypervariable region 1 (HVR1) have a high
degree of sequence variability between different HCV isolates
(Weiner et al., 1991; Kurosaki et al., 1994; Alfonso et al., 2004), and
have been suggested to contain a dominant neutralizing epitope
(Farci et al., 1996). Haqshenas et al. (2007) generated a chimeric
GBV-B encoding the HVR1 of HCV and were able to demon-
strate successful infection in vivo. However, marmosets cleared
the virus as early as 3 weeks post-infection and therefore it was
not possible to generate anti-HVR1 antibodies in these animals.
Recently, Li et al. (2014) generated GBV-B chimeras contain-
ing full-length HCV genes of either whole structural core or all
envelope proteins. Infected marmosets remained viremic up to
44 weeks and exhibited signiﬁcant liver pathology and a strong T
cell response. Given the restricted tropism of HCV to humans and
chimpanzees, the capability of this chimera with HCV envelope
proteins to infect marmosets and primary marmoset hepatocyte
cultures could suggest conserved viral receptors and virus–host
interactions.
GBV-B DRUG TESTING MODELS
The GBV-B infection model has also been used for the screen-
ing of candidate vaccines and other therapeutic agents such as
interferon and ribavarin. Ribavarin treatment reduced viral RNA
levels by four logs by inducing error prone replication in cul-
ture, but in vivo treatment showed no obvious reduction in
viremia (Lanford et al., 2001). Bright et al. (2004) demonstrated
the efﬁcacy of HCV antivirals against GBV-B by showing that
HCV NS3 protease inhibitors could block replication both in
vitro and in vivo. Furthermore, a trans-lactam, GW0014X was
also found capable of preventing GBV-B infection in marmosets.
RNA interference, used in gene silencing, has also been applied
therapeutically in GBV-B-infected animals. Marmosets adminis-
tered cationic liposome-encapsulated siRNA (CLsiRNA) directed
againstGBV-B virus controlled virus replication inmanner depen-
dent on CL-siRNA dosing, reaching levels of complete inhibition
at 5 mg/kg (Yokota et al., 2007).
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CONCLUDING REMARKS
During the last decade various reports have shown the utility of
GBV-B infection as a surrogate model for HCV. Although the
GBV-B/marmoset model has a lower chronicity rate, it has a
number of advantages over other animal models including lower
cost, availability of chimeric viruses, effectiveness of HCV drugs
against GBV-B, and a tractable disease course. While the devel-
opment of new antivirals has changed the landscape of the HCV
ﬁeld, the cost-prohibitive nature of these treatments underscores
the ongoing need for a successful vaccine. Thus, we propose that
the GBV-B/marmoset model warrants revisiting as a thoughtful
research tool for development of immunotherapeutics, newantivi-
rals, and vaccine modalities for eventual translation into human
studies.
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